Hepatopulmonary syndrome in patients with porto-sinusoidal vascular disorder: Characteristics and outcome
Year: 2024
Type: article
Study design: Observational Study
Abstract: Background & Aims Porto-sinusoidal vascular disorder (PSVD) is a rare cause of portal hypertension. Data on hepatopulmonary syndrome (HPS) in PSVD are limited. This study aimed to determine the associated factors, plasma mediators, and evolution of HPS in patients with PSVD. Methods Multicenter observational study of patients with PSVD with signs of portal hypertension in whom contrast-enhanced transthoracic echocardiography (CE-TTE) was performed. Results Among 196 patients with PSVD who underwent CE-TTE in 17 centers, 14 (7% [95% confidence interval 3–11%]) had a confirmed diagnosis of HPS. Patients with HPS more frequently had a genetic disorder associated with PSVD (50% vs. 6%, p <0.001), especially telomere biology disorders ( p <0.001). Liver function was less preserved in patients with HPS, because they had lower prothrombin index (63% vs. 86%, p = 0.04), higher serum total bilirubin (37 μmol/L vs. 14 μmol/L, p <0.001), and lower serum albumin (32 g/L vs. 38 g/L, p <0.001). HPS tended to be associated with more portal venule obliterations ( p = 0.085) and with nodular liver architecture ( p = 0.069). Plasma concentrations of Angiopoietin-2, ICAM3, and Tie2 were higher in patients with HPS ( p = 0.02, p = 0.04, p = 0.01, respectively). Out of the 14 patients with HPS, five underwent liver transplantation after a median follow-up of 34 months. Overall cumulative incidence of liver-related events and of death was similar between patients with and without HPS, when considering liver transplantation for HPS as a competing risk. Conclusions HPS in patients with PSVD was associated with genetic disorders, less preserved liver function, and higher plasma concentrations of angiogenic mediators. When applying HPS model for end-stage liver disease exception policy for liver transplantation, overall survival of patients with PSVD and HPS was similar to that of patients with PSVD without HPS. Impact and implications: Hepatopulmonary syndrome (HPS) is a rare complication of porto-sinusoidal vascular disorder (PSVD). This multicentric study found that patients with PSVD and HPS had less preserved liver function, and harbored genetic disorders more frequently (especially telomere biology disorders) than patients without HPS. HPS did not negatively impact transplantation-free survival when applying HPS MELD exception policy for liver transplantation through a competitive risk analysis. Our findings suggest that patients with PSVD with respiratory symptoms and/or telomere biology disorders may benefit from systematic screening for HPS.
Source: JHEP Reports
Authors: Sabrina Sidali, Ylang Spaes, Kinan El Husseini, Odile Goria, Vincent Mallet, Armelle Poujol-Robert, Anne Gervais, Adrien Lannes, Dominique Thabut, Jean-Baptiste Nousbaum, Isabelle Hourmand-Ollivier, Charlotte Costentin, Alexandra Heurgué, Pauline Houssel-Debry, Sophie Hillaire, Nathalie Ganne-Carrié, Nicolas Drilhon, Shanta Ram Valainathan, Lucile Moga, Marion Tanguy, Estelle Marcault, Aurélie Plessier, François Durand, Sarah Raevens, Valérie Paradis, Agnès Cachier, Laure Elkrief, Pierre-Emmanuel Rautou
Institutions: Inserm, Université Paris Cité, Hôpital Beaujon, Assistance Publique – Hôpitaux de Paris, Centre de Recherche sur l'Inflammation, Hôpital Charles-Nicolle, Centre Hospitalier Universitaire de Rouen, Hôpital Bichat-Claude-Bernard, Hôpital Cochin, Hôpital Saint-Antoine, Hôpital Louis-Mourier, Centre Hospitalier Universitaire d'Angers, Sorbonne Université, Pitié-Salpêtrière Hospital, Centre de Recherche Saint-Antoine, Fondation pour l’innovation en Cadiométabolisme et Nutrition, Centre Hospitalier Régional Universitaire de Brest, Centre Hospitalier Universitaire de Caen Normandie, Centre National de la Recherche Scientifique, Institut pour l'avancée des biosciences, Université Grenoble Alpes, Centre Hospitalier Universitaire de Reims, Centre Hospitalier Universitaire de Rennes, Hôpital Foch, Université Sorbonne Paris Nord, Hôpital Avicenne, Ghent University Hospital, Ghent University, Université de Tours, Centre Hospitalier Universitaire de Tours
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,900
Funders: Ministry of Health, European Commission, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale, Fondation ARC pour la Recherche sur le Cancer, Ministère des Solidarités et de la Santé, Horizon 2020 Framework Programme
Awards: G1190173965, DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES, TimE frame ControL of Inflammation by canonical and non-canonical autophagy to Prevent fatty liver diSease progrEssion, G265113304, G4077682647, G434337789, G4656594441, G4667364679, G5186833093, Deciphering HEArt-liVEr commuNication in nonalcohoLic fattY liver disease, G7259991030, exTRACellular vesicles as biomarKers, European Joint Programme on Rare Diseases, G8471630636, Université de Paris
OpenAlex ID: W4405651122
